Founded in 2021, Norroy bioscience Co., Ltd. is a biomedical enterprise dedicated to pioneering research and innovative diagnosis and treatment in the field of radio pharmaceuticals. Norroy's focused approach on addressing unmet clinical needs in urinary system tumors and gastrointestinal tumors has driven a fast proof of concept and rapid commercialization of our two-wheeled strategy. This strategic development aligns with China's original layout research innovation in nuclear medicine, emphasizing excellence in both the First Class and Best in Class dimensions.
Recently, Sunmao Medical has reached an important international milestone: SUNMAO Medical's Product, M1 Multifunc...
Recently, the two new drug clinical trial (IND) applications submitted by Nuoyu Medicine to the FDA for the original ...
Recently, Norroy's independent innovative radiation therapy drug 177Lu-NY108(NYM032) injection has been granted c...
28
2023/12
Norroy's first original nuclear drug for Renal cancer was approved for clinical trials in both China and US
Following the FDA approval, the radiological d...
MORE >>
27
2023/12
Sunmao Medical on the international journal of Annals of Nuclear Medicine (ANM), the international influence increased greatly!
In December 2023, Development and applicati...
MORE >>
24
2023/11
Sunmao medical radiation safety permit approved
In November 2023, Wuxi Sunmao Medical ...
MORE >>
27
2023/10
Norroy’s renal cancer pipeline 18F-NY104 entered the first Ph0 clinical trial
Recently, 18F-NY104 diagnostic nuclear drug...
MORE >>
86-0510-88786189Address: No.35-208, Changjiangnan Road, XinWu District, Wuxi, China
Mail address: bd@norroybioscience.com
Website: 4000576365.cn
